COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Central Venous Catheter Insertion Site and Colonization in Pediatric Cardiac Surgery (PRECiSE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03282292
Recruitment Status : Unknown
Verified November 2017 by Marco Ranucci, IRCCS Policlinico S. Donato.
Recruitment status was:  Recruiting
First Posted : September 13, 2017
Last Update Posted : November 7, 2017
Information provided by (Responsible Party):
Marco Ranucci, IRCCS Policlinico S. Donato

Brief Summary:
Randomized controlled trial comparing femoral vs internal jugular insertion site of central venous catheters (CVC) in newborns and infants undergoing cardiac surgery. The experimental hypothesis is that the jugular insertion site is superior to the femoral in terms of catheter colonization.

Condition or disease Intervention/treatment Phase
Central Line-associated Bloodstream Infection (CLABSI) Central Venous Catheter Associated Bloodstream Infection Heart; Surgery, Heart, Functional Disturbance as Result Congenital Heart Disease Newborn; Infection Procedure: Internal jugular vein CVC insertion Not Applicable

Detailed Description:

Background: in adult patients, the femoral site of insertion of CVC is notoriously at higher risk of colonization and central-line associated bloodstream infection (CLABSI) than other sites (jugular or subclavian). In pediatric patients, the femoral site is more commonly used than in adult patients, but there is no sound data on catheter colonization and CLABSI related to the insertion site. The experimental hypothesis of this randomized controlled trial (RCT) is that the jugular insertion site is less likely to induce catheter colonization and CLABSI than the femoral site.

Methods: 160 patients under 1 year and scheduled for cardiac surgery will be included in this RCT; patients will be randomly allocated to the jugular (J Group) or Femoral (F Group). CVC insertion will be performed by one out of three selected expert operators.

The primary endpoint is the catheter colonization based on identification of bacterial grow into the catheter at removal time; CLABSI and CRBSI rate based on the same bacterial identification into the catheter tip and in the blood culture performed in case of signs and symptoms of infection.

Secondary endpoints are mechanical complications defined as arterial puncture immediately identified during procedure, hemothorax and pneumothorax; and procedural difficulty during insertion defined as number of attempts, no guidewire progress, duration of the procedure (time from the completion of the sterile precaution barriers and the catheter fixation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized controlled trial
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Central Venous Catheter Insertion Site and Catheter Colonization and Bloodstream Infection in Pediatric Cardiac Surgery
Actual Study Start Date : September 12, 2017
Estimated Primary Completion Date : September 12, 2019
Estimated Study Completion Date : October 12, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Surgery

Arm Intervention/treatment
Experimental: Jugular
CVC insertion in the left or right internal jugular vein
Procedure: Internal jugular vein CVC insertion
Double lumen CVC insertion in the internal jugular vein

Active Comparator: Femoral
CVC insertion in the right or left femoral vein
Procedure: Internal jugular vein CVC insertion
Double lumen CVC insertion in the internal jugular vein

Primary Outcome Measures :
  1. CVC colonization [ Time Frame: 14 days ]
    CVC positive culture after removal

  2. CRBSI [ Time Frame: 14 days ]
    Positive CVC culture and blood stream infection for the same organism

  3. CLABSI [ Time Frame: More than 48 hours ]
    A laboratory-confirmed bloodstream infection where central line was in place for more than 48h.

Secondary Outcome Measures :
  1. Mechanical complications [ Time Frame: 1 day ]
    Defined as arterial puncture; hemothorax; pneumothorax

  2. Procedural difficulty [ Time Frame: 1 hour ]
    Defined by number of attempts; no guidewire progress

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 1 Year   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Planned cardiac surgery Age <1 year Eligibility for both insertion sites (jugular and femoral) for CVC Availability of at least one out of the three chosen expert operators

Exclusion Criteria:

Emergency surgery Known vascular anatomic anomalies Previous cardiac surgery in the last 6 months No expert operator availability Intensive Care unit before surgery Central venous catheter inside at the time of randomization

Withdraw criteria (only for the first endpoint):

Impossibility to placement catheter in the selected site.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03282292

Layout table for location contacts
Contact: Marco Ranucci, MD +390252774754
Contact: Simona Silvetti, MD +390252774754

Layout table for location information
IRCCS Policlinico S.Donato Recruiting
San Donato Milanese, Milan, Italy, 20097
Contact: Marco Ranucci, MD    00390252774 ext 754   
Principal Investigator: Marco Ranucci, MD         
Principal Investigator: Simona Silvetti, MD         
Sub-Investigator: Tommaso Aloisio, MD         
Sub-Investigator: Anna Cazzaniga, MD         
Sponsors and Collaborators
IRCCS Policlinico S. Donato
Layout table for investigator information
Study Director: Marco Ranucci, MD IRCCS Policlinico San Donato
Publications of Results:

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Marco Ranucci, Director Clinical Research, IRCCS Policlinico S. Donato Identifier: NCT03282292    
Other Study ID Numbers: PedCVC
First Posted: September 13, 2017    Key Record Dates
Last Update Posted: November 7, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The dataset will be made available at reasonable request
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: November 2017 - November 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Heart Diseases
Cardiovascular Diseases